课题基金 / 基金详情

Mechanism of Immunoglobulin Hypermutation

Mechanism of Immunoglobulin Hypermutation
免疫球蛋白超突变机制
批准号:
7146985
负责人:
URSULA B STORB
金额:
$37.84万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-05-01 至 2011-05-31

项目摘要

项目成果

URSULA B STORB的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This is a proposal for the continuation of studies of the molecular basis of somatic hypermutation (SHM) of immunoglobulin (Ig) genes. The discovery of the cytidine deaminase, AID, has clearly identified the deamination of C as the first step in SHM. Based on the current knowledge, the mutation process can be viewed as follows: AID specifically associates with Ig genes (and a few other genes, such as BCL6, IgD, and IgD. AID creates C to U deaminations in both the top and bottom strand of the targeted gene, starting within 200 bp from the promoter and extending for about 1 to 2 kb. The 3' end of the gene is spared. The uracil is repaired in an error-prone fashion, resulting in an excess of transitions over transversions from all four nucleotides. The details of the process are not understood. They can be considered as three major complexes of questions. 1) How are Ig genes (and a few other genes) specifically targeted by AID and how are the mutations restricted to the first 1-2 kb from the promoter? 2) Since AID in vitro is highly restricted to C-deamination in single-stranded, not double-stranded DMA, how can both strands be equally targeted during SHM? 3) How does error-prone repair become involved in the process and how are mutations from A and T created? It is proposed in this grant application to study these questions. The planned experiments are important for determining how the varied repertoire of Ig genes is created with the potential to react against any foreign antigenic substance, including tumor cell antigens. Somatic hypermutation has also been implicated in autoimmune diseases. Furthermore, many B cell lymphomas arise apparently as a consequence of the somatic mutation process. It is likely that understanding the components involved in somatic mutation will aid in understanding the genetic and environmental causes of autoimmunity, and the treatment of infectious diseases and tumors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
AID in somatic mutation of immunoglobulin genes
  • 批准号:
    7573127
  • 项目类别:
  • 资助金额:
    $19.5万
  • 财政年份:
    2009
  • 负责人:
    URSULA B STORB
  • 依托单位:
AID in somatic mutation of immunoglobulin genes
  • 批准号:
    7767761
  • 项目类别:
  • 资助金额:
    $23.17万
  • 财政年份:
    2009
  • 负责人:
    URSULA B STORB
  • 依托单位:
Identification of the DNA methylation/chromatin modifier Ssm1
  • 批准号:
    7616702
  • 项目类别:
  • 资助金额:
    $7.68万
  • 财政年份:
    2008
  • 负责人:
    URSULA B STORB
  • 依托单位:
Immunoglobulin Somatic Mutation
  • 批准号:
    6826842
  • 项目类别:
  • 资助金额:
    $26.18万
  • 财政年份:
    2002
  • 负责人:
    URSULA B STORB
  • 依托单位:
国内基金
海外基金
免标记CRISPR-RNA适配体与门逻辑分子诊断新方法研究
  • 批准号:
    2026JJ50010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    应站明
  • 依托单位:
RNA m6A修饰通过调控FDX1介导的铜死亡参与补阳还五汤抗脑缺血再灌注损伤作用机制的研究
  • 批准号:
    2026JJ81091
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    刘亮
  • 依托单位:
基于合成生物标志物的超多重RNA数字化检测平台用于肿瘤精准诊断和分期评估
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    程子译
  • 依托单位:
Dead-box解旋酶DDX23通过调控RNA高级结构促进肝癌细胞恶性生物学行为的分子机制研究
  • 批准号:
    JCZRLH202600588
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位: